Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 12, 2017 - Issue 8
Submit an article Journal homepage
782
Views
11
CrossRef citations to date
0
Altmetric
Review

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project

Lucas MorenoPaediatric Phase I-II Clinical Trials Unit, Paediatric Haematology & Oncology, Hospital Niño Jesus, Madrid, Spain;Instituto de Investigación Sanitaria La Princesa, Madrid, Spain;Paediatric Drug Development, Children and Young People’s Unit, Royal Marsden Hospital, London, UKCorrespondence[email protected]
View further author information
,
Hubert CaronEmma Children’s Hospital, Amsterdam, Netherlands;Hoffman-La Roche, Basel, SwitzerlandView further author information
,
Birgit GeoergerDepartment of Paediatric and Adolescent Oncology, Institut Gustave Roussy, Villejuif, FranceView further author information
,
Angelika EggertDepartment of Pediatric Oncology and Hematology, Charite University Hospital, Berlin, GermanyView further author information
,
Gudrun SchleiermacherDepartment of Paediatric, Adolescents and Young Adults Oncology and INSERM U830, Institut Curie, Paris, FranceView further author information
,
Penelope BrockDepartment Paediatric Oncology, Great Ormond Street Hospital, London, UKView further author information
,
Dominique Valteau-CouanetDepartment of Paediatric and Adolescent Oncology, Institut Gustave Roussy, Villejuif, FranceView further author information
,
Louis CheslerPaediatric Drug Development, Children and Young People’s Unit, Royal Marsden Hospital, London, UK;Division of Clinical Studies, Institute of Cancer Research, London, UKView further author information
,
Johannes H SchulteDepartment of Pediatric Oncology and Hematology, Charite University Hospital, Berlin, GermanyView further author information
,
Katleen De PreterCentre for Medical Genetic, Ghent University, Ghent, BelgiumView further author information
,
Jan MolenaarPrincess Maxima Center for Pediatric Oncology, University of Amsterdam, Amsterdam, NetherlandsView further author information
,
Alexander SchrammDepartment of Pediatric Oncology, University of Essen, Essen, GermanyORCID Iconhttp://orcid.org/0000-0001-7670-7529View further author information
ORCID Icon,
Martin EilersTheodor Boveri Institute and Comprehensive Cancer Center Mainfranken, Biocenter, University of Wurzburg, Wurzburg, GermanyView further author information
,
Tom Van MaerkenCentre for Medical Genetic, Ghent University, Ghent, BelgiumView further author information
,
John Inge JohnsenDepartment of Women’s and Children’s Health, Karolinska Institute, Stockholm, SwedenORCID Iconhttp://orcid.org/0000-0003-1277-812XView further author information
ORCID Icon,
Michelle GarrettSchool of Biosciences, University of Kent, Canterbury, UKView further author information
,
Sally L GeorgePaediatric Drug Development, Children and Young People’s Unit, Royal Marsden Hospital, London, UK;Division of Clinical Studies, Institute of Cancer Research, London, UKView further author information
,
Deborah A. TweddleWolfson Childhood Cancer Research Centre, Newcastle University, Newcastle, UKView further author information
,
Per KognerDepartment of Women’s and Children’s Health, Karolinska Institute, Stockholm, SwedenORCID Iconhttp://orcid.org/0000-0002-2202-9694View further author information
ORCID Icon,
Frank BertholdDepartment of Pediatric Oncology and Hematology, University of Cologne, Cologne, GermanyView further author information
,
Jan KosterPrincess Maxima Center for Pediatric Oncology, University of Amsterdam, Amsterdam, NetherlandsView further author information
,
Giuseppe BaronePaediatric Drug Development, Children and Young People’s Unit, Royal Marsden Hospital, London, UK;Division of Clinical Studies, Institute of Cancer Research, London, UKView further author information
,
Elizabeth R TuckerPaediatric Drug Development, Children and Young People’s Unit, Royal Marsden Hospital, London, UK;Division of Clinical Studies, Institute of Cancer Research, London, UKView further author information
,
Lynley MarshallPaediatric Drug Development, Children and Young People’s Unit, Royal Marsden Hospital, London, UK;Division of Clinical Studies, Institute of Cancer Research, London, UKView further author information
,
Ralf HeroldEuropean Medicines Agency, London, UKView further author information
,
Jaroslav SterbaMasaryk University, University Hospital, Brno, Czech Republic;Department of Pediatric Oncology, International Clinical Research Center, St. Anne’s University Hospital, Brno, Czech Republic;RECAMO, Masaryk Memorial Cancer Centre, Brno, Czech RepublicView further author information
,
Koen NorgaPediatric Hematology/Oncology Unit, Antwerp University Hospital, Antwerp, BelgiumView further author information
,
Gilles VassalDepartment of Clinical Research, Gustave Roussy, Paris-Sud University, Paris, FranceView further author information
&
Andrew DJ PearsonPaediatric Drug Development, Children and Young People’s Unit, Royal Marsden Hospital, London, UK;Division of Clinical Studies, Institute of Cancer Research, London, UKView further author information
 show all
Pages 801-811 | Received 23 Feb 2017, Accepted 06 Jun 2017, Published online: 26 Jun 2017

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Lucy Swift, Chunfen Zhang, Tanya Trippett & Aru Narendran. (2019) Potent in vitro and xenograft antitumor activity of a novel agent, PV-10, against relapsed and refractory neuroblastoma. OncoTargets and Therapy 12, pages 1293-1307.
Read now
Fabio Morandi, Loredana Amoroso, Alessandra Dondero, Roberta Castriconi, Stefano Parodi, Roberto Luksch, Fiorina Casale, Aurora Castellano, Alberto Garaventa, Alessandro Moretta, Cristina Bottino, Mirco Ponzoni & Maria Valeria Corrias. (2018) Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma. OncoImmunology 7:9.
Read now

Articles from other publishers (9)

Jaclynne H. Nader, Florence Bourgeois, Rochelle Bagatell, Lucas Moreno, Andrew D. J. Pearson & Steven G. DuBois. (2022) Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020. Pediatric Blood & Cancer 70:5.
Crossref
Lijun Zhao, Junying Fan, Chunyang Zhang, Zhenjun Zhang & Jun Dong. (2023) CircRANBP17 modulated KDM1A to regulate neuroblastoma progression by sponging miR-27b-3p. Open Medicine 18:1.
Crossref
Angela Martinez-Monleon, Hanna Kryh Öberg, Jennie Gaarder, Ana P. Berbegall, Niloufar Javanmardi, Anna Djos, Marek Ussowicz, Sabine Taschner-Mandl, Inge M. Ambros, Ingrid Øra, Bengt Sandstedt, Klaus Beiske, Ruth Ladenstein, Rosa Noguera, Peter F. Ambros, Lena Gordon Murkes, Gustaf Ljungman, Per Kogner, Susanne Fransson & Tommy Martinsson. (2022) Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup. Scientific Reports 12:1.
Crossref
Wenke Jin, Huidan Tan, Junhao Wu, Gu He & Bo Liu. (2022) Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions. Drug Discovery Today 27:1, pages 246-256.
Crossref
Eriko Y. Saito, Kengo Saito, Tomoro Hishiki, Ayako Takenouchi, Takeshi Saito, Yoshiharu Sato, Keita Terui, Tadashi Matsunaga, Hiroshi Shirasawa & Hideo Yoshida. (2020) Sindbis viral structural protein cytotoxicity on human neuroblastoma cells. Pediatric Surgery International 36:10, pages 1173-1180.
Crossref
Lucy Swift, Chunfen Zhang, Olga Kovalchuk, Jessica Boklan, Tanya Trippett & Aru Narendran. (2019) Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma. Investigational New Drugs 38:3, pages 690-699.
Crossref
John Inge Johnsen, Cecilia Dyberg & Malin Wickström. (2019) Neuroblastoma—A Neural Crest Derived Embryonal Malignancy. Frontiers in Molecular Neuroscience 12.
Crossref
Sanja Aveic, Marcella Pantile, Pierfrancesco Polo, Viktoryia Sidarovich, Marilena De Mariano, Alessandro Quattrone, Luca Longo & Gian Paolo Tonini. (2018) Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors. Cancer Cell International 18:1.
Crossref
Shana Claeys, Geertrui Denecker, Robrecht Cannoodt, Candy Kumps, Kaat Durinck, Frank Speleman & Katleen De Preter. (2017) Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome. Oncotarget 8:63, pages 106820-106832.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.